Published in final edited form as:

Am J Kidney Dis. 2020 January ; 75(1): 54–60. doi:10.1053/j.ajkd.2019.05.027.

***APOL1* Nephropathy Risk Alleles and Mortality in African American Adults: A Cohort Study**

Orlando M. Gutiérrez, MD, MMSc^{1,2}, Marguerite R. Irvin, PhD², Neil A. Zakai, MD⁴, Rakhi P. Naik, MD, MHS⁴, Ninad S. Chaudhary, MBBS, MPH², Michelle M. Estrella, MD, MHS⁵, Sophie Limou, PhD⁶, Suzanne E. Judd, PhD³, Mary Cushman, MD, MSc⁴, Jeffrey B. Kopp, MD⁷, Cheryl A. Winkler, PhD⁸

¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

²Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA

³Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA

⁴Departments of Medicine and Pathology & Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA

⁵Kidney Health Research Collaborative, Department of Medicine, Univeristy of California, San Francisco and San Francisco VA Medical Center, San Francisco, CA, USA

⁶University of Nantes, Nantes, France

⁷National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA

⁸Basic Research Laboratory, National Cancer Institute, National Institutes of Health, and Leidos Biomedical Research, Frederick National Laboratory, Frederick, MD, USA

Abstract

Rationale & Objective: *APOL1* nephropathy risk alleles are associated with the development of chronic kidney disease (CKD) in African Americans. Although CKD is an established risk factor for mortality, associations of *APOL1* risk alleles with mortality are uncertain.

Study Design: Prospective cohort

Correspondence: Cheryl A. Winkler, Basic Research Laboratory, National Institute of Cancer Research, Leidos Biomedical Research, National Laboratory for Cancer Research at Frederick, 8560 Progress Drive, Frederick, Maryland 21702, USA. winklerc@mail.nih.gov.

Authors' Contributions: conceived and designed study: OMG, MRI, JBK, CAW; involved in data acquisition: RPN, SEJ, NAZ, MC; analyzed data: OMG, NC; involved in data interpretation: OMG, MRI, NAZ, RPN, MME, SL, SEJ, MC, JBK, CAW. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

Financial Disclosure: The authors declare that they have no relevant financial interests.

Disclaimer: The content of this publication does not necessarily reflect the views or policies of the NINDS, NIA, NIDDK, NCI, NIH, or the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Settings & Participants: 10,380 African-American and 17,485 white-American participants of the REasons for Geographic and Racial Differences in Stroke (REGARDS) study.

Exposures: *APOL1* nephropathy risk alleles

Outcomes: All-cause and cause-specific mortality

Analytical Approach: Cox proportional hazards models were used to examine the association of *APOL1* high-risk genotypes (2 risk alleles) vs. *APOL1* low-risk genotypes (0/1 risk alleles) with all-cause and cause-specific mortality in African Americans; and to examine the risk of all-cause mortality in African Americans with high-risk genotypes vs. African Americans with low-risk genotypes and white Americans.

Results: *APOL1* high-risk participants were younger and had higher prevalence of albuminuria than low-risk participants. There was no statistically significant association of *APOL1* high-risk vs. low-risk genotypes with all-cause mortality in models adjusted for sociodemographic variables, comorbidities and kidney function (HR, 0.88; 95% CI, 0.77-1.01). After further adjustment for genetic ancestry in a subset with available data, a statistically significant association emerged (HR, 0.81; 95%CI, 0.69-0.96). The associations differed by CKD status ($p_{\text{interaction}} = 0.04$), with African Americans with high-risk genotypes having lower risk of mortality than those with low-risk genotypes in fully adjusted models (HR, 0.78; 95%CI, 0.62-0.99) among those with CKD, but not those without CKD (HR, 0.84; 95%CI, 0.66-1.05). Compared to white Americans, African Americans with high-risk genotypes had a similar rate of mortality, whereas African Americans with low-risk genotypes had a higher rate of mortality (HR, 1.07; 95%CI, 1.00-1.14) in fully-adjusted models.

Limitations: Lack of follow-up measures of kidney function.

Conclusions: African Americans with high-risk *APOL1* genotypes had lower mortality than those with low-risk genotypes in multivariable-adjusted models including genetic ancestry.

Keywords

apolipoprotein L1 (APOL1); racial/ethnic disparities; chronic kidney disease (CKD); genetic risk factor; African American; risk allele; mortality; *APOL1* genotype; CKD progression; nephropathy; genetic differences; survival

INTRODUCTION

Two coding alleles in the apolipoprotein L1 gene (*APOL1*) are associated with the development and progression of kidney disease in African Americans.^{1, 2} Chronic kidney disease (CKD) is an established risk factor for all-cause mortality,³ suggesting that *APOL1* nephropathy risk alleles may shorten survival in African Americans with high-risk genotypes comprising any combination of the two risk alleles. Consistent with this possibility, a report from the Cardiovascular Health Study (CHS) showed that carriage of high-risk *APOL1* genotypes was associated with higher risk of mortality than carriage of low-risk *APOL1* genotypes (zero or one risk allele).⁴ In contrast, other studies showed no differences in mortality⁵⁻⁷ or paradoxically, longer survival in African Americans with high-risk versus low-risk nephropathy genotypes.⁸⁻¹⁰

The reasons for the inconsistencies in these findings are unclear, but may be related to the characteristics of the study populations being examined. Whereas CHS was a population-based cohort of older adults, the studies finding no or opposite associations of *APOL1* high-risk genotypes with mortality examined individuals who were younger on average and had established CKD or diabetes or both. Prior studies were also limited by having relatively few mortality events, reducing their statistical power to examine the association of *APOL1* nephropathy genotype with survival outcomes within key subgroups. Accordingly, in the current study, we examined the association of *APOL1* nephropathy genotypes with all-cause mortality in 10,380 African-American participants of the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. In addition, we examined whether these associations differed by subgroups of baseline kidney disease, diabetes and age.

METHODS

Study Population

The REGARDS study is a population-based investigation of stroke incidence and cognitive function in African Americans and white Americans 45 years of age. The study design has been reported elsewhere.¹¹ Briefly, participants were recruited from the 48 contiguous US states and the District of Columbia. The study oversampled African Americans and persons residing in the stroke belt/buckle regions of the US. Between January 2003 and October 2007, 30,239 individuals were enrolled (42% African American, 55% women). Participants or their proxies were contacted every 6 months by telephone to assess outcomes including death. The REGARDS Study protocol was approved by the Institutional Review Boards governing research in human subjects at the participating centers and all participants provided informed consent.

Genotype Assessment/Primary Exposure

APOL1 alleles (G1 [rs73885319A>G, S342G] and G2 [Rs71785313 TTATAA/-N388Y389/-]) were genotyped in African-American participants using TaqMan SNP Genotyping Assays (Applied Biosystems/ThermoFisher Scientific).^{1, 12} *APOL1* high-risk status was defined as the presence of 2 risk alleles (G1/G1, G2/G2, or G1/G2) versus the low-risk status, defined as having 1 or 0 risk alleles (G1/G0, G2/G0, G0/G0), representing a recessive model. A subset of participants had available genomic array data (Illumina exome chip) to estimate population substructure (n=6,714) via principal components generated using EIGENSOFT software.^{13, 14}

Outcomes of interest

The primary outcome of interest was all-cause mortality and the secondary outcome of interest was cause-specific mortality. Participants or their proxies were queried every 6 months by telephone for hospitalizations or physician visits. Deaths were detected by report of the next-of-kin or through other sources (Social Security Death Index, National Death Index). All-cause mortality through March 30th, 2017 were available for the current analyses.

To adjudicate cause of death, death certificates, medical records and autopsy reports were obtained and reviewed by trained clinicians.¹⁵ Deaths were reviewed by two adjudicators, and disagreements on the cause of death were decided by committee. For the current study, death was categorized as being related to cardiovascular (defined as death from definite, probable or possible myocardial infarction; stroke; sudden death; heart failure; other cardiac; not cardiac but other cardiovascular; or pulmonary embolism), cancer, or other causes. Adjudication for cause-specific mortality was available through December 31st, 2014.

Covariate data collection at baseline

Data on covariates of interest were collected during a baseline in-home visit (including the collection of a blood and spot urine sample) and a separate computer assisted telephone interview. Information on age, race, sex, smoking status, lipid-lowering drugs and antihypertensive medication use was collected by self-report and review of pill bottles during the in-home visit. Systolic and diastolic blood pressures were defined as the average of two seated blood pressure measures taken after a 5 minute rest. Diabetes was defined as fasting serum glucose ≥ 126 mg/dL, non-fasting serum glucose ≥ 200 mg/dL, or use of anti-diabetes medications. Serum creatinine was calibrated to an international isotope dilution mass spectroscopic-traceable standard, measured by colorimetric reflectance spectrophotometry. We calculated eGFR using the CKD-EPI equation.¹⁶ Albumin and creatinine were measured using the random spot urine specimen by nephelometry (BN ProSpec Nephelometer, Dade Behring, Marburg, Germany) and Modular-P chemistry analyzer (Roche/Hitachi, Indianapolis, IN), respectively. Spot urinary albumin-creatinine ratio (UACR) was calculated in mg/g. Abnormal ACR was defined as ACR ≥ 30 mg/g. Individuals with an eGFR < 60 ml/min/1.73m² or an ACR ≥ 30 mg/g were classified as having CKD at baseline. Serum high sensitivity C-reactive protein (hsCRP) was measured using a high-sensitivity particle-enhanced immunonephelometric assay.

Statistical Analyses

We compared participant characteristics by *APOL1* risk allele count (0 or 1 vs. 2) in African-American participants using the χ^2 test for categorical variables and ANOVA for continuous variables. We calculated incidence rates and 95% confidence intervals of each outcome for each risk category (0 or 1 vs. 2). After confirming the proportionality assumption, Cox proportional hazards models were used to assess the association of *APOL1* high-risk vs. low-risk status (recessive model) with all-cause mortality in sequential models. Model 1 was unadjusted. Model 2 adjusted for age, sex, current smoking, income, diabetes, body mass index, blood pressure, history of coronary heart disease and lipid parameters total cholesterol and HDL-C). Since high-risk *APOL1* genotypes associate with kidney disease, in Model 3 we further adjusted for eGFR and log-transformed ACR to determine whether a potential association of *APOL1* genotype with mortality was in part mediated by kidney disease. Model 4 adjusted for principal components for ancestry in the subset of individuals with available data. Secondary analyses examined the association of *APOL1* risk alleles with all-cause mortality using dominant and additive models, and examined the association of *APOL1* with cause-specific mortality (cardiovascular, cancer or other). In addition, we examined the association of self-reported race with all-cause mortality, with race categorized as white American (reference group), African American with low-risk genotypes, and

African American with high-risk genotypes. In all models, we examined for effect modification by age (above or below the median), diabetes and CKD status on the association of *APOL1* genotypes with all-cause mortality by testing the statistical significance of interaction terms. All analyses were carried out using SAS v. 9.4.

RESULTS

Study population

A total of 10,605 African-American participants had *APOL1* genotype data. After excluding 225 with missing follow-up data, 10,380 African-American participants were available for analysis. Of these, 1,320 had 2 risk alleles (12.7% of the study population).

Association of *APOL1* risk status with all-cause mortality

After a mean 8.4 $\pm$ 3.7 (standard deviation) years of follow-up, a total of 2,563 African-American participants died. Table 1 shows baseline characteristics of the study population by *APOL1* genotype. As compared to participants with *APOL1* low-risk genotypes, participants with *APOL1* high-risk genotypes were younger, had a lower mean eGFR, higher median ACR, higher mean total cholesterol concentrations, and a higher incidence of end-stage kidney disease.

Crude incidence rates of all-cause mortality and hazard ratios (HR) of all-cause mortality by *APOL1* risk-status are shown in Table 2. The incidence of all-cause mortality was lower in *APOL1* high-risk as compared to low-risk participants. There was no statistically significant association of *APOL1* genotypes with all-cause mortality in the unadjusted model (HR, 0.90; 95% confidence interval [95%CI], 0.79-1.02); after adjustment for age, sex, current smoking, income, diabetes, body mass index, blood pressure, history of coronary heart disease, total cholesterol, and HDL-C (HR, 0.96; 95%CI, 0.84-1.09); or after further adjustment for eGFR and ACR (HR, 0.88; 95%CI, 0.77-1.01). A statistically significant association emerged after further adjustment for principal components of ancestry in the subset of participants with available data (HR, 0.81; 95%CI, 0.69-0.96). Results were qualitatively similar when analyses were repeated using additive or dominant models (Tables S1 & S2).

The association of *APOL1* genotype with all-cause mortality differed by the presence or absence of CKD ($P_{interaction}=0.04$) but not diabetes ($P_{interaction}=0.37$) or age ($P_{interaction}=0.67$). Baseline characteristics of study participants by *APOL1* genotype and CKD status are presented in Table S3. The risk of all-cause mortality was lower in CKD participants with high-risk vs. low-risk genotypes in the unadjusted analysis, and after adjustment for age, sex, current smoking, income, diabetes, body mass index, blood pressure, history of coronary heart disease, total cholesterol, HDL-C, eGFR, and ACR (HR, 0.78; 95%CI, 0.64-0.95; Table S4). Further adjustment for principal components of ancestry did not meaningfully change the results in the subset of CKD participants with available data (HR, 0.78; 95%CI, 0.62-0.99). The association of high-risk genotypes with mortality was in the same direction but did not reach statistical significance in the fully-adjusted model in

individuals without CKD (HR, 0.84; 95%CI, 0.66-1.05). Results were qualitatively similar when analyses were repeated using additive or dominant models (Tables S5 & S6)

Association of APOL1 genotype with cause-specific mortality

Table 3 presents the association of *APOL1* genotype with cause-specific mortality (cardiovascular vs. cancer vs. other death). There were no statistically significant associations of *APOL1* genotypes with deaths from cardiovascular disease events or cancer. As compared to African Americans with *APOL1* low-risk genotypes, African Americans with *APOL1* high-risk genotypes had a lower risk of death from other causes in the unadjusted model (HR, 0.78; 95%CI, 0.63-0.97), after adjustment for sociodemographic variables, co-morbidities, and kidney function (HR, 0.72; 95%CI, 0.55-0.93), and after further adjustment for principal components of ancestry (HR, 0.62; 95%CI, 0.45-0.86).

Association of race and APOL1 genotype with all-cause mortality

Table S7 depicts the association of race and *APOL1* risk status with all-cause mortality. As compared to white Americans, African Americans with low-risk genotypes had a higher risk of all-cause death in the unadjusted analysis (HR, 1.16; 95%CI, 1.10-1.22) in models adjusted for sociodemographic variables and comorbidities (HR, 1.08; 95%CI, 1.01-1.15), and in models further adjusted for kidney function (HR, 1.07; 95%CI, 1.00-1.14). In contrast, there was no statistically significant difference in mortality comparing African Americans with high-risk genotypes to white Americans in any model.

The association of race with all-cause mortality differed by CKD status ($P_{\text{interaction}}=0.02$). In individuals with CKD at baseline, African-American participants with *APOL1* high-risk genotypes had lower mortality than African-American participants with *APOL1* low-risk genotypes and white-American participants in the crude model (Table S8; HR, 0.73; 95%CI, 0.60-0.87) but this association was no longer statistically significant in the multivariable adjusted models. In individuals without CKD at baseline, there were no statistically significant differences in survival in white Americans as compared to African Americans irrespective of *APOL1* genotype status in any models.

Discussion

African Americans with two *APOL1* nephropathy risk alleles are at increased risk of the development and progression of CKD. Kidney disease is the 9th most common cause of death in the US, and likely contributes to many other deaths by increasing the risk of cardiovascular disease. As such, carriage of *APOL1* high-risk genotypes would logically be expected to be linked to an increased risk of death. The results of the current study, and others,⁸⁻¹⁰ show opposite findings—African Americans with high-risk genotypes had a similar or lower risk of mortality than African Americans with low-risk genotypes and White Americans. Further, whereas African Americans with low-risk genotypes had a higher risk of mortality than white Americans, no such association was observed when comparing African Americans with high-risk genotypes to white Americans.

Multiple prior studies examined the association of *APOL1* nephropathy risk alleles with mortality, but the results have been inconsistent. A study of 798 African-American and 4964

white-American participants of CHS showed that African Americans with high-risk genotypes had higher risk of all-cause mortality than African Americans with low-risk genotypes or white Americans.⁴ In contrast, no association was noted between *APOL1* genotype and survival in the African American Study of Kidney Disease and Hypertension (AASK),⁵ the Atherosclerosis Risk in Communities (ARIC) study,⁶ or in the Systolic Blood Pressure Intervention Trial (SPRINT).⁷ More surprisingly, two separate reports from the African American-Diabetes Heart Study showed that carriage of greater numbers of *APOL1* nephropathy risk alleles was associated with reduced risk of all-cause mortality (whether examining additive, dominant or recessive models).^{8,9} In addition, in a study of African Americans initiating hemodialysis in the Southeastern US, carriage of two *APOL1* nephropathy risk alleles was associated with longer survival than carriage of zero or one risk alleles in those without diabetes, whereas no differences in survival were noted in those with diabetes.¹⁰

The current study both confirms and contradicts prior findings. Much like the African American-Diabetes Heart Study and the study of African Americans initiating hemodialysis, we found that *APOL1* high-risk genotypes were associated with better, not worse, survival in the fully adjusted models including genetic ancestry. We also found that African Americans with low-risk genotypes had higher risk of mortality than white Americans, whereas no differences in mortality were noted when comparing African Americans with high-risk genotypes to white Americans, opposite to what was reported in CHS. The reasons for these findings are unclear. There is some evidence that carriage of *APOL1* nephropathy risk variants may lower propensity for vascular calcification.^{9,17} In addition, we previously showed that individuals with *APOL1* high-risk genotypes have higher circulating concentrations of HDL subtypes that may protect against atherogenesis.¹⁸ It is important to note, nonetheless, that the protective association of *APOL1* high-risk genotypes was most pronounced for causes of death other than cardiovascular disease or cancer in the current study. This suggests there may be non-traditional pathways by which *APOL1* high-risk alleles are protective, such as via effects on innate immunity that have been largely unexplored beyond known links with trypanosomiasis. It is also important to note that the association of *APOL1* high-risk genotypes with lower all-cause mortality became statistically significant only after adjustment for genetic ancestry in the subset of individuals with available data despite the drop in sample size. The associations of genetic ancestry with complex disease are varied, with some data suggesting that greater African ancestry is protective, whereas other data suggest the opposite.¹⁹⁻²¹ It is known that *APOL1* high-risk genotype frequencies vary within African descent populations and adjustment for population substructure revealed confounding for the relationship between *APOL1* and survival in our data. Given heterogeneity in African descent populations in the US and the decrease in our sample size upon adjustment for ancestry, larger studies are needed to investigate this relationship. Finally, some studies have reported a protective relationship between African ancestry and atherosclerotic disease,²² and although the reduction in all-cause mortality in REGARDS was not driven by cardiovascular disease, future studies are warranted to determine if *APOL1* could contribute to this protective phenomenon.

Unlike prior reports, we did not find that associations of *APOL1* genotypes with mortality differed by diabetes status. Instead, the association of *APOL1* nephropathy risk alleles and

mortality appeared to be stronger in individuals with CKD at baseline than in those without CKD at baseline. We interpret these latter results with caution given the possibility of collider bias—that is, individuals with CKD and high-risk genotypes may represent a healthier subset since their kidney disease is more likely related to carriage of *APOL1* risk alleles than individuals with CKD and low-risk genotypes, whose kidney disease may be more strongly related to a greater burden of comorbidities (diabetes, heart disease, etc.) linked to shortened survival. These findings need to be confirmed in other studies.

Our study had a number of strengths including the large sample size and prospective follow-up, allowing for the capture of a large number of death events and examination of associations within key subgroups. Our study also had limitations. We did not have ancestry informative markers on the entire cohort, which might have strengthened the *APOL1* associations. We could not completely exclude the possibility that our findings could be explained by survival bias (i.e., African Americans with high-risk genotypes who survived long enough to be enrolled in the REGARDS study represent a healthier subgroup than their low-risk genotype counterparts). While possible, there were no major differences in baseline characteristics of the two populations that would suggest that *APOL1* high-risk participants were a much healthier subgroup at the time of their enrollment into the REGARDS study. Another limitation was that we did not have sufficient data on follow-up measures of kidney function, precluding us from examining to what extent differences in the change in eGFR and albuminuria over time impacted the results. Finally, we were not able to determine which causes of death in the “other” category drove the association of *APOL1* genotype with mortality.

In summary, African Americans carrying *APOL1* high-risk genotypes had lower risk of death than African Americans with low-risk genotypes in fully adjusted models including genetic ancestry. Further, African Americans with low-risk genotypes had significantly higher risk of all-cause mortality than white Americans, whereas no such difference was observed when comparing African Americans with high-risk genotypes to white Americans, suggesting that carriage of high-risk genotypes may attenuate racial disparities in survival.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements:

The authors thank the other investigators, the staff, and the participants of the REGARDS study for their valuable contributions. A full list of participating REGARDS investigators and institutions can be found at <http://www.regardsstudy.org>.

Support: This study was supported by a cooperative agreement U01 NS041588 from the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Services. OMG was supported by R01NS080850, U01DK102730, and K24DK116180 from the National Institutes of Health, and a Strategically Focused Research Network in Disparities in Cardiovascular Disease grant from the American Heart Association (15SFDRN25620022). JBK was supported by the Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD. CAW was funded in part with federal funds from the National Cancer Institute (NCI), National Institutes of Health, under contract HHSN26120080001E and supported in part by the Intramural Research Program of the NIH, NCI, Center for Cancer Research. Representatives from the funding sources did not have a role in study design, data collection, analysis, reporting or the decision to submit for publication.

REFERENCES

1. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. *Science*. 2010;329(5993): 841–845. [PubMed: 20647424]
2. Parsa A, Kao WH, Xie D, et al. APOL1 risk variants, race, and progression of chronic kidney disease. *N Engl J Med*. 2013;369(23): 2183–2196. [PubMed: 24206458]
3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med*. 2004;351(13): 1296–1305. [PubMed: 15385656]
4. Mukamal KJ, Tremaglio J, Friedman DJ, et al. APOL1 Genotype, Kidney and Cardiovascular Disease, and Death in Older Adults. *Arterioscler Thromb Vasc Biol*. 2016;36(2): 398–403. [PubMed: 26634651]
5. Chen TK, Appel LJ, Grams ME, et al. APOL1 Risk Variants and Cardiovascular Disease: Results From the AASK (African American Study of Kidney Disease and Hypertension). *Arterioscler Thromb Vasc Biol*. 2017;37(9): 1765–1769. [PubMed: 28572159]
6. Grams ME, Rebholz CM, Chen Y, et al. Race, APOL1 Risk, and eGFR Decline in the General Population. *J Am Soc Nephrol*. 2016;27(9): 2842–2850. [PubMed: 26966015]
7. Freedman BI, Rocco MV, Bates JT, et al. APOL1 renal-risk variants do not associate with incident cardiovascular disease or mortality in the Systolic Blood Pressure Intervention Trial. *Kidney Int Rep*. 2017;2(4): 713–720. [PubMed: 28758155]
8. Chan GC, Divers J, Russell GB, et al. FGF23 Concentration and APOL1 Genotype Are Novel Predictors of Mortality in African Americans With Type 2 Diabetes. *Diabetes Care*. 2018;41(1): 178–186. [PubMed: 29113983]
9. Freedman BI, Langefeld CD, Lu L, et al. APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes. *Kidney Int*. 2015;87(1): 176–181. [PubMed: 25054777]
10. Ma L, Langefeld CD, Comeau ME, et al. APOL1 renal-risk genotypes associate with longer hemodialysis survival in prevalent nondiabetic African American patients with end-stage renal disease. *Kidney Int*. 2016;90(2): 389–395. [PubMed: 27157696]
11. Howard VJ, Cushman M, Pulley L, et al. The reasons for geographic and racial differences in stroke study: objectives and design. *Neuroepidemiology*. 2005;25(3): 135–143. [PubMed: 15990444]
12. Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. *J Am Soc Nephrol*. 2011;22(11): 2129–2137. [PubMed: 21997394]
13. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. *PLoS Genet*. 2006;2(12): e190. [PubMed: 17194218]
14. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet*. 2006;38(8): 904–909. [PubMed: 16862161]
15. Halanych JH, Shuaib F, Parmar G, et al. Agreement on cause of death between proxies, death certificates, and clinician adjudicators in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. *Am J Epidemiol*. 2011; 173(11): 1319–1326. [PubMed: 21540327]
16. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Annals of internal medicine*. 2009;150(9): 604–612. [PubMed: 19414839]
17. Ito K, Bick AG, Flannick J, et al. Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. *Circ Res*. 2014;114(5): 845–850. [PubMed: 24379297]
18. Gutierrez OM, Judd SE, Irvin MR, et al. APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans. *Nephrol Dial Transplant*. 2016;31(4): 602–608. [PubMed: 26152403]
19. Bentley AR, Rotimi CN. Interethnic Differences in Serum Lipids and Implications for Cardiometabolic Disease Risk in African Ancestry Populations. *Global heart*. 2017;12(2): 141–150. [PubMed: 28528248]

20. Campbell MC, Tishkoff SA. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. *Annual review of genomics and human genetics*. 2008;9: 403–433.
21. Reiner AP, Carlson CS, Ziv E, Iribarren C, Jaquish CE, Nickerson DA. Genetic ancestry, population sub-structure, and cardiovascular disease-related traits among African-American participants in the CARDIA Study. *Hum Genet*. 2007;121(5): 565–575. [PubMed: 17356887]
22. Divers J, Palmer ND, Langefeld CD, et al. Genome-wide association study of coronary artery calcified atherosclerotic plaque in African Americans with type 2 diabetes. *BMC Genet*. 2017;18(1): 105. [PubMed: 29221444]

Table 1.Baseline characteristics of African-American REGARDS participants by *APOL1* genotype.

	0/1 APOL1 risk allele (n=9060)	2 APOL1 risk alleles (n= 1320)	P-value
Age, mean (SD)	64.2 (9.3)	63.4 (8.9)	0.003
Male sex, n (%)	3502 (39)	504 (38)	0.7
Region, n (%)			0.9
Stroke belt/buckle	4618 (51)	674 (51)	
Non-belt/buckle	4437 (49)	646 (49)	
Income <\$20,000/year, n (%)	2398 (26)	366 (28)	0.3
Education < high school, n (%)	1776 (20)	254 (19)	0.5
Current smoking, n (%)	1597 (18)	210 (16)	0.1
Body mass index, mean (SD)	30.8 (6.7)	30.9 (6.6)	0.3
Blood pressure			
Systolic, mean (SD)	130.9 (17.4)	131.3 (17.3)	0.4
Diastolic, mean (SD)	78.4 (10.2)	78.9 (9.9)	0.1
Diabetes, n(%)	2663 (30)	394 (30)	0.8
History of heart disease, n(%)	1383 (16)	190 (15)	0.4
Hypertension, n(%)	6461 (71)	947 (72)	0.7
Medication use, n(%)			
Blood pressure medications	6205 (69)	926 (70)	0.2
Statins	2635 (29)	383 (29)	0.9
Aspirin	3439 (38)	536 (41)	0.07
eGFR, mean (SD)	88.6 (23.6)	86.1 (24.5)	<0.001
eGFR < 60 ml/min/1.73m ² , n(%)	1085 (12.1)	179 (13.6)	0.1
UACR, median [IQR]	7.8 [4.6,19.3]	9.2 [4.9,26.0]	<0.001
UACR ≥ 30 mg/g, n(%)	1634 (18.1)	293 (22.2)	<0.001
hsCRP, median [IQR]	2.9 [1.26,7]	2.9 [1.2,6.6]	0.6
Total cholesterol, mean (SD)	192.7 (41.4)	195.7 (39.6)	0.01
HDL-C, mean (SD)	53.3 (15.9)	54.2 (16.8)	0.08
Triglycerides, mean (SD)	113.9 (75.5)	114.0 (64.4)	0.9
Developed ESKD			0.001
No.	229	54	
Incidence, 95%CI *	299 (263-341)	486 (373-635)	

Unless otherwise indicated, values for continuous variables given as mean $\pm$ SD or median [interquartile range]; for categorical variables, as count (percentage).

Abbreviations: HS, high school; eGFR, estimated glomerular filtration rate; UACR, urinary albumin-creatinine ratio; hsCRP, high-sensitivity C-reactive protein; HDL-C, high-density lipoprotein cholesterol; ESKD, end-stage kidney disease; 95%CI, 95% confidence interval

* per 100,000 person-years of follow-up

Table 2.

All-cause mortality by *APOL1* risk status in African-American participants of REGARDS.

	0/1 <i>APOL1</i> risk alleles	2 <i>APOL1</i> risk alleles
n/N	2261/9060	302/1320
Incidence rate (95% CI) *	29.6 (28.4-30.9)	26.7 (23.9-29.9)
Hazard Ratio (95% CI)		
Model 1 [†]	1.00 (reference)	0.90 (0.79-1.02)
Model 2 [†]	1.00 (reference)	0.96 (0.84-1.09)
Model 3 [†]	1.00 (reference)	0.88 (0.77-1.01)
Model 4 [†]	1.00 (reference)	0.81 (0.69-0.96)

n/N: No. of events/ no. at risk

* Per 1000 person-years of follow-up

[†] Hazard ratio (95% confidence interval)

Model 1: Unadjusted. (n/N=2,563/10,380)

Model 2: adjusted for age, sex, current smoking, income, diabetes, body mass index, blood pressure, history of coronary heart disease, total cholesterol, and high-density lipoprotein-cholesterol. (events/N=2080/8680)

Model 3: adjusted for variables in model 1 and estimated glomerular filtration rate (eGFR) and log-transformed urinary albumin-creatinine ratio (UACR). (n/N=1936/8,397)

Model 4: adjusted for age, sex, total cholesterol, high-density lipoprotein-cholesterol, eGFR, log-transformed UACR and PCS for ancestry in the subset of participants with available ancestry data. (n/N=1399/5,895)

Table 3.cause-specific mortality by *APOL1* risk status in African-American participants of REGARDS

	0/1 <i>APOL1</i> risk alleles	2 <i>APOL1</i> risk alleles
Cardiovascular		
n/N	677/9060	102/1320
Model 1	1.00 (reference)	1.02 (0.83,1.25)
Model 2	1.00 (reference)	1.15 (0.92,1.43)
Model 3	1.00 (reference)	1.04 (0.83,1.31)
Model 4	1.00 (reference)	0.98 (0.75,1.31)
Cancer		
n/N	488/9060	68/1320
Model 1	1.00 (reference)	0.94 (0.73,1.21)
Model 2	1.00 (reference)	1.00 (0.76,1.32)
Model 3	1.00 (reference)	0.99 (0.75,1.32)
Model 4	1.00 (reference)	0.89 (0.64,1.25)
Other		
n/N	789/9060	91/1320
Model 1	1.00 (reference)	0.78 (0.63,0.97)
Model 2	1.00 (reference)	0.84 (0.66,1.08)
Model 3	1.00 (reference)	0.72 (0.55,0.93)
Model 4	1.00 (reference)	0.62 (0.45,0.86)

n/N: No. of events/ no. at risk

Model 1: unadjusted (*Cardiovascular*: n/N=779/10,380; *Cancer*: n/N=556/10380; *Other*: n/N=880/10,380)**Model 2:** adjusted for age, sex, current smoking, income, diabetes, body mass index, blood pressure, history of coronary heart disease, total cholesterol, high-density lipoprotein-cholesterol. (*Cardiovascular*— events/N=642/8680; *Cancer*—events/N=459/8680; *Other*—events/N=696/8680)**Model 3:** adjusted for variables in model 1 and estimated glomerular filtration rate, and log-transformed urinary albumin-creatinine ratio. (*Cardiovascular*: n/N=595/8397; *Cancer*: n/N=437/8397; *Other*: n/N=633/8397)**Model 4:** adjusted for for variables in model 2 and principal components for ancestry in the subset of participants with available ancestry data. (*Cardiovascular*: n/N=415/5895; *Cancer*: n/N=321/5895; *Other*: n/N=460/5895)